Highlights from the SNO 2020 virtual conference

The SNO 2020 virtual conference included many presentations on new and potential treatments, particularly for glioblastoma. The following three studies were particularly interesting, showing the promising advances that are being made.

Novel T cell-enabling therapies plus checkpoint inhibition in newly diagnosed glioblastoma

New data came from a study of a combination of vaccination for known tumor-associated antigens – elicited by synthetic DNA plasmids for hTERT, WT-1, and PSMA with synchronous IL-12 stimulation – with PD-L1 blockade using cemiplimab, in newly diagnosed glioblastoma (presentation LTBK-01).